α-smooth muscle actin-positive fibroblasts correlate with poor survival in hepatocellular carcinoma

JIGNESH G. PARIKH1, ANAND KULKARNI1 and CAMEILA JOHNS1,2

1Department of Pathology, University of Tennessee Health Science Center, Memphis, TN 38163; 2Department of Pathology, Veterans Affairs Medical Center, Memphis, TN 38104, USA

Received May 30, 2013; Accepted November 26, 2013

DOI: 10.3892/ol.2013.1720

Abstract. The current case-control study was conducted to assess the value of activated fibroblasts with high α-smooth muscle actin (α-SMA) expression as an indicator of survival in hepatocellular carcinoma (HCC) patients. In total, 47 patients diagnosed with HCC who underwent a liver biopsy at the Veterans Affairs Medical Center (Memphis, TN, USA) between January 2000 and December 2009, and 10 age- and gender-matched controls with normal liver biopsy samples were included in the study. The immunohistochemical staining for α-SMA was performed and classified qualitatively and quantitatively within tumor stroma and perisinusoidal spaces. HCC patients with high qualitative and quantitative expression of α-SMA revealed a statistically significant negative correlation with 3-year (odds ratio (OR), 0.021 and 0.111; P=0.001 and 0.0302, respectively) and 1.5-year (OR, 0.040 and 0.051; P=0.0330 and 0.0492, respectively) survival rates in comparison with low expression. The results of the present study demonstrated a predictive role of high qualitative and quantitative expression in activated fibroblasts for poor survival in patients with HCC.

Introduction

Activated fibroblasts or myofibroblasts with α-smooth muscle actin (α-SMA) expression are considered to be the main cellular constituents of reactive stroma in a number of solid tumors (1). These activated fibroblasts have been proposed to be important in promoting tumor progression and metastasis by releasing growth factors, extracellular matrix proteins and angiogenic factors (2,3). The hepatic stellate cell (HSC), an important hepatic stromal cell, is known to be activated or transdifferentiated into a myofibroblast-like cell through intercellular communication between HSCs and damaged hepatocytes in various liver tumors, including hepatocellular carcinoma (HCC) (4). These activated HSCs demonstrate a high expression of α-SMA and are considered to be a vital stromal component in HCC (5). Increasing evidence has indicated that activated HSCs play a critical role in promoting HCC cell proliferation and invasiveness (6,7). In addition, HSCs are now being considered as a new potential therapeutic target in patients with HCC (3). To the best of our knowledge, no direct evidence has been identified documenting a correlation between fibroblast activation and survival in HCC patients. The aim of the present study was to assess the value of activated fibroblasts with high α-SMA expression as an indicator for survival in patients with HCC.

Patients and methods

A case-control study was performed at the Veterans Affairs Medical Center (Memphis, TN, USA) following appropriate Institutional Review Board approval. A review of the computerized hospital records was conducted to identify the cases of patients diagnosed with HCC who had undergone a liver biopsy between January 2000 and December 2009. A total of 10 age- and gender-matched cases with no histopathological abnormality on liver biopsy were also identified and used as controls. The clinical information with regard to age and survival period were obtained for all study cases. The immunohistochemical staining for α-SMA was performed on the formalin-fixed, paraffin-embedded tissue sections of all study and control cases. The α-SMA staining in the HSCs within the tumor stroma and perisinusoidal spaces was qualitatively classified into the following 4 groups compared with vascular smooth muscle cells (VSMCs): 0, no staining; +1, staining intensity considerably lower than VSMCs (Fig. 1B); +2, staining intensity lower than VSMCs; and +3, staining intensity similar to that of VSMCs (Fig. 1C and D). In addition, the α-SMA staining was quantitatively classified into the following 4 groups: 0, ≤1 positive cell/high-power field (hpf); +1, <10 positive cells/hpf (Fig. 1B); +2, 10-20 positive cells/hpf; and +3, >20 positive cells/hpf (Fig. 1C and 1D). Qualitative and quantitative classification was performed by a fellowship-trained gastrointestinal pathologist without matching knowledge of the clinical data. For statistical analysis, grades 0 and +1 were categorized as low expression and grades +2 and +3 as high expression.
**Results**

A total of 47 patients (age range, 45-85 years; mean age, 64.45 years) were diagnosed with HCC between January 2000 and December 2009. All the study subjects subsequently succumbed to their condition. The survival period following diagnosis ranged between 1 and 94 months (mean survival, 19 months). All the study and control subjects were male. Positive staining for α-SMA in control tissue was mainly observed in VSMCs (Fig 1A; inset) and in extremely few cells in the perisinusoidal spaces (Fig. 1A). High qualitative (strong) and quantitative (extensive) expression of α-SMA was revealed in 41 and 42 of the 47 patients, respectively. Low qualitative (weak) and quantitative (sparse) expression of α-SMA was revealed in 6 and 5 of the 47 patients, respectively. Strong and extensive expression of α-SMA revealed a statistically significant negative correlation with the 3-year [OR, 0.021 and 0.111; 95% confidence interval (CI), 0.002-0.234 and 0.015-0.810; P=0.001 and 0.0302, respectively] and 1.5-year (OR, 0.040 and 0.051; 95% CI, 0.002-0.771 and 0.002-0.990; P=0.0330 and 0.0492, respectively) survival rates in comparison with weak and sparse expression (Table I). No significant correlation was identified between age and α-SMA expression.

| Characteristics | α-SMA staining intensity | α-SMA-positive HSC |
|-----------------|--------------------------|---------------------|
|                 | High, n (%) | Low, n (%) | OR (95% CI) | P-value | High, n (%) | Low, n (%) | OR (95% CI) | P-value |
| Age, years      |             |             |             |         |             |             |             |         |
| ≤62             | 23 (49)     | 5 (11)      | 0.156       | 0.103   | 19 (40)     | 4 (9)       | 0.206       | 0.174   |
| >62             | 24 (51)     | 1 (2)       |             |         | 23 (49)     | 1 (2)       |             |         |
| 3-year survival |             |             |             |         |             |             |             |         |
| >3              | 9 (19)      | 5 (11)      | 0.021       | 0.0016  | 6 (13)      | 3 (6)       | 0.111       | 0.0302  |
| ≤3              | 38 (81)     | 1 (2)       |             |         | 36 (77)     | 2 (4)       |             |         |
| 1.5-year survival |             |             |             |         |             |             |             |         |
| >1.5            | 20 (43)     | 6 (13)      | 0.040       | 0.0330  | 15 (32)     | 5 (11)      | 0.051       | 0.0492  |
| ≤1.5            | 27 (57)     | 0 (0)       |             |         | 27 (57)     | 0 (0)       |             |         |

α-SMA, α-smooth muscle actin; HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence interval.
The interaction of tumor cells with surrounding stromal cells has been recognized to promote tumor development by affecting cell proliferation, survival and invasiveness (7). As important hepatic stromal cells, HSCs have been considered to play a key role in liver fibrosis when excessively activated in various liver diseases, including HCC (8). HCC is one of the most common types of malignant cancer in humans, with an overall 5-year survival rate of only 3% in the United States (9). Surgical resection is the choice of treatment for HCC, however, this is not feasible when patients present in late stages of the disease (10). In addition, radiotherapy and chemotherapy are not effective in advanced disease (10).

Activated HSCs that express extremely high levels of \( \alpha - \text{SMA} \) have emerged as potentsuppressors of hepatic immunity by affecting T-cell responses and thus, play a vital role in the progression of HCC (6,7,11,12). Previous studies have also indicated that activated HSCs are potential targets for HCC treatment (4).

The current study revealed that the detection of \( \alpha - \text{SMA} \)-expressing fibroblasts in HCC provides valuable prognostic information. As \( \alpha - \text{SMA} \) is a routinely used and relatively inexpensive immunohistochemical stain, the majority of pathology laboratories efficiently employ \( \alpha - \text{SMA} \) to predict future survival in HCC patients. The present study also supports the role of \( \alpha - \text{SMA} \)-expressing activated HSCs in promoting carcinogenesis, which is considered to be a possible target for future antitumor therapy in HCC.

In the present study, due to lack of follow-up staging information for all the patients, the results were not corrected for stage, metastasis and other factors. Due to this same reason, it was not possible to determine whether \( \alpha - \text{SMA} \) is predictive of metastasis-related survival or is an independent predictive factor. Multicenter-based large studies with detailed and frequent staging evaluation data, which enables multifactorial analysis, are recommended to improve the present understanding of the role of \( \alpha - \text{SMA} \)-expressing fibroblasts for predicting poor survival in HCC.

In conclusion, the current study demonstrated a predictive role of strong and extensive \( \alpha - \text{SMA} \) expression in activated fibroblasts for poor survival in HCC patients. Strong expression of \( \alpha - \text{SMA} \) is an excellent marker to anticipate poor 3-year survival (OR, 0.021; 95% CI, 0.002-0.234; \( P = 0.001 \)). Qualitative \( \alpha - \text{SMA} \) expression levels in activated fibroblasts appear to present an improved marker for predicting survival compared with quantitative expression.

### References

1. Micke P and Ostman A: Exploring the tumor environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 9: 1217-1233, 2005.
2. Olumi AF, Grossfeld GD, Hayward SW, et al: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59: 5002-5011, 1999.
3. Chuaysri C, Thuwajit P, Paupairoj A, et al: Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol Rep 21: 957-969, 2009.
4. Kuang P, Zhao W, Su W, et al: 18β-glycyrrhetinic acid inhibits hepatocellular carcinoma development by reversing hepatic stellate cell-mediated immunosuppression in mice. Int J Cancer 132: 1831-1841, 2013.
5. Hautekeete ML and Geerts A: The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch 430: 195-207, 1997.
6. Carpino G, Morini S, Ginanni CS, et al: Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis 37: 349-356, 2005.
7. Desmoulière A, Guyot C and Gabbiani G: The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 48: 509-517, 2004.
8. Friedman SL: Mechanism of hepatic fibrogenesis. Gastroenterology 134: 1655-1669, 2008.
9. Desmet VJ and Rosai J: Liver: tumors and tumorlike conditions. In: Rosai and Ackerman's Surgical Pathology. Rosai J (ed). 10th Edition. Mosby Elsevier, New York, pp944-953, 2011.
10. Bruix J and Sherman M: American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022, 2011.
11. Yu MC, Chen CH, Liang X, et al: Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology 40: 1312-1321, 2004.
12. Chen CH, Kuo LM, Chang Y, et al: In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology 44: 1171-1181, 2006.